On Nov. 17, 2025, Sandoz announced that TYRUKO® (natalizumab-sztn) is available to patients in the US. Developed by Polpharma Biologics, TYRUKO® is the first and only US Food and Drug Administration (FDA) approved natalizumab biosimilar for the treatment of relapsing forms of multiple sclerosis (MS).

TYRUKO® is approved by the FDA as monotherapy to treat all indications covered by reference medicine Tysabri®* (natalizumab), including relapsing forms of MS and Crohn’s disease in adults.

TYRUKO® is available through a Risk Evaluation and Mitigation Strategy (REMS) program designed to inform prescribers, infusion site healthcare providers and patients about the risk of progressive multifocal leukoencephalopathy (PML) associated with natalizumab, including increased risk of PML with the presence of anti-JCV antibodies, longer treatment duration and prior immunosuppressant use¹. The program warns against concurrent use with antineoplastic, immunosuppressant or immunomodulating agents and, in patients who are immunocompromised, promotes early diagnosis of PML and timely discontinuation of TYRUKO® in the event of suspected PML.

Sandoz entered into a global commercialization agreement for biosimilar natalizumab in 2019. Under this agreement, Polpharma Biologics will maintain responsibility for the development of the medicine, manufacturing and supply of the drug substance. Through an exclusive global license, Sandoz has the rights to commercialize and distribute it in all markets. In addition to the US, TYRUKO® is now available in 14 European countries.

Sandoz has partnered with Labcorp, a global leader of innovative and comprehensive laboratory services, to develop and validate a laboratory-developed test (LDT) for detecting the presence of anti-JCV antibodies. Labcorp will offer the TYRUKO® JCV Testing Program at no cost to eligible patients, with Sandoz covering the cost of the test.